• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4: Rice John Mccune Jr. returned 27,449 shares to the company, closing all direct ownership in the company

    1/31/23 2:20:26 PM ET
    $VIVO
    Power Generation
    Utilities
    Get the next $VIVO alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
    X
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    1. Name and Address of Reporting Person*
    Rice John McCune Jr.

    (Last) (First) (Middle)
    3471 RIVER HILLS DRIVE

    (Street)
    CINCINNATI OH 45244

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    MERIDIAN BIOSCIENCE INC [ VIVO ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    01/31/2023
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 01/31/2023 D 27,449 D (1) 0 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (Right to Buy) $16.2 01/31/2023 D 12,000 (2) 01/25/2028 Common Stock 12,000(2) $17.8(2) 0 D
    Stock Option (Right to Buy) $16.97 01/31/2023 D 8,740 (3) 01/24/2029 Common Stock 8,740(3) $17.03(3) 0 D
    Stock Option (Right to Buy) $21.36 01/31/2023 D 5,796 (4) 01/27/2031 Common Stock 5,796(4) $12.64(4) 0 D
    Stock Option (Right to Buy) $20.75 01/31/2023 D 5,656 (5) 01/26/2032 Common Stock 5,656(5) $13.25(5) 0 D
    Explanation of Responses:
    1. The shares were disposed of pursuant to the Agreement and Plan of Merger dated as of July 7, 2022 (the "Merger Agreement") by and among the Issuer and SD Biosensor, Inc., a corporation with limited liability organized under the laws of the Republic of Korea whereby, immediately prior to the effective time of the merger contemplated therein (the "Effective Time"), all issued and outstanding shares of Issuer common stock were converted into the right to receive $34.00 per share in cash and, when so converted, automatically cancelled.
    2. The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment.
    3. The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment.
    4. The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment.
    5. The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment.
    /s/ F. Mark Reuter, as Attorney-in-fact for John McCune Rice Jr. 01/31/2023
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $VIVO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VIVO

    DatePrice TargetRatingAnalyst
    2/7/2022$28.00 → $30.00Buy
    HC Wainwright & Co.
    11/15/2021$27.00 → $28.00Buy
    HC Wainwright & Co.
    8/9/2021$30.00 → $27.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $VIVO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HC Wainwright & Co. reiterated coverage on Meridian Bioscience with a new price target

    HC Wainwright & Co. reiterated coverage of Meridian Bioscience with a rating of Buy and set a new price target of $30.00 from $28.00 previously

    2/7/22 6:13:53 AM ET
    $VIVO
    Power Generation
    Utilities

    HC Wainwright & Co. reiterated coverage on Meridian Bioscience with a new price target

    HC Wainwright & Co. reiterated coverage of Meridian Bioscience with a rating of Buy and set a new price target of $28.00 from $27.00 previously

    11/15/21 6:32:31 AM ET
    $VIVO
    Power Generation
    Utilities

    HC Wainwright & Co. reiterated coverage on Meridian Bioscience with a new price target

    HC Wainwright & Co. reiterated coverage of Meridian Bioscience with a rating of Buy and set a new price target of $27.00 from $30.00 previously

    8/9/21 6:33:26 AM ET
    $VIVO
    Power Generation
    Utilities

    $VIVO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    VivoPower Appoints Group Finance Director

    LONDON, UK / ABU DHABI, UAE, July 20, 2026 (GLOBE NEWSWIRE) -- VivoPower PLC (NASDAQ:VIVO) ("VivoPower" or the "Company"), a B Corp-certified global developer and owner of powered land and data center infrastructure for AI compute applications, today announced the appointment of Syed Muhammad Nouman, FCA, as Group Finance Director, effective from July 20, 2026. Mr. Nouman will serve as the Company’s Principal Financial Officer and Principal Accounting Officer for SEC reporting purposes, as ratified by the Company’s Audit Committee. Mr. Nouman began his career at PwC, where he developed a strong foundation in audit and financial reporting. He is a Fellow Chartered Accountant (FCA) with mor

    7/20/26 9:00:00 AM ET
    $VIVO
    Power Generation
    Utilities

    Noble Capital Markets Initiates Equity Research Coverage on VivoPower

    LONDON, UK / OSLO, NORWAY, July 13, 2026 (GLOBE NEWSWIRE) -- VivoPower PLC (NASDAQ:VIVO) ("VivoPower" or the "Company"), a B Corp-certified global developer and owner of powered land and data center infrastructure for AI compute applications, is pleased to announce that Noble Capital Markets has initiated company-sponsored equity research coverage on the Company with an Outperform rating and a $10.00 price target. The research report, authored by Noble Capital Markets Senior Research Analyst Michael Kupinski, is available on Channelchek, along with the latest news, market data, and additional information on Tectonic. Management encourages investors to review the report and visit Channelc

    7/13/26 1:00:00 PM ET
    $VIVO
    Power Generation
    Utilities

    VivoPower Targets Up To USD$4 million Incremental Annualized EBITDA from Battery Energy Storage Integration at Norway Data Center

    BESS integration targeted to unlock additional FCR-N, FCR-D and FFR Grid Reserve revenue streams  Design would preserve the site's full leasable capacity for AI compute tenants Final investment decision subject to board approval, post completion of external feasibility study LONDON, UK / OSLO, NORWAY, July 06, 2026 (GLOBE NEWSWIRE) -- VivoPower PLC (NASDAQ:VIVO) ("VivoPower" or the "Company"), a B Corp-certified global developer and owner of powered land and data center infrastructure for AI compute applications, today announced that it is progressing a formal technical and commercial feasibility study for the integration of a battery energy storage system ("BESS") at its 41.5 MW Mo i

    7/6/26 3:00:00 PM ET
    $VIVO
    Power Generation
    Utilities

    $VIVO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Jeavons Peter

    3 - VivoPower PLC (0001681348) (Issuer)

    4/8/26 8:54:33 AM ET
    $VIVO
    Power Generation
    Utilities

    SEC Form 4: Williams Felicia returned 10,274 shares to the company, closing all direct ownership in the company

    4 - MERIDIAN BIOSCIENCE INC (0000794172) (Issuer)

    1/31/23 2:22:23 PM ET
    $VIVO
    Power Generation
    Utilities

    SEC Form 4: Sazdanoff Catherine returned 16,424 shares to the company, closing all direct ownership in the company

    4 - MERIDIAN BIOSCIENCE INC (0000794172) (Issuer)

    1/31/23 2:21:33 PM ET
    $VIVO
    Power Generation
    Utilities

    $VIVO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    December 10, 2021 - Coronavirus (COVID-19) Update: December 10, 2021

    For Immediate Release: December 10, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: On December 9, 2021, the FDA updated the SARS-CoV-2 Viral Mutations: Impact on COVID-19 Tests web page to share the latest information. The update added new information about the Meridian Bioscience, Inc. Revogene SARS-CoV-2 test, inc

    12/10/21 1:56:40 PM ET
    $VIVO
    Power Generation
    Utilities

    $VIVO
    SEC Filings

    View All

    SEC Form 6-K filed by VivoPower PLC

    6-K - VivoPower PLC (0001681348) (Filer)

    7/20/26 10:15:00 AM ET
    $VIVO
    Power Generation
    Utilities

    SEC Form 6-K filed by VivoPower PLC

    6-K - VivoPower PLC (0001681348) (Filer)

    7/17/26 5:25:01 PM ET
    $VIVO
    Power Generation
    Utilities

    Amendment: SEC Form 6-K/A filed by VivoPower PLC

    6-K/A - VivoPower PLC (0001681348) (Filer)

    7/7/26 5:25:36 PM ET
    $VIVO
    Power Generation
    Utilities

    $VIVO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Meridian Bioscience Inc. (Amendment)

    SC 13G/A - MERIDIAN BIOSCIENCE INC (0000794172) (Subject)

    2/9/23 11:27:43 AM ET
    $VIVO
    Power Generation
    Utilities

    SEC Form SC 13D/A filed by Meridian Bioscience Inc. (Amendment)

    SC 13D/A - MERIDIAN BIOSCIENCE INC (0000794172) (Subject)

    2/3/23 2:06:19 PM ET
    $VIVO
    Power Generation
    Utilities

    SEC Form SC 13G/A filed by Meridian Bioscience Inc. (Amendment)

    SC 13G/A - MERIDIAN BIOSCIENCE INC (0000794172) (Subject)

    1/31/23 11:06:04 AM ET
    $VIVO
    Power Generation
    Utilities

    $VIVO
    Leadership Updates

    Live Leadership Updates

    View All

    VivoPower Appoints Group Finance Director

    LONDON, UK / ABU DHABI, UAE, July 20, 2026 (GLOBE NEWSWIRE) -- VivoPower PLC (NASDAQ:VIVO) ("VivoPower" or the "Company"), a B Corp-certified global developer and owner of powered land and data center infrastructure for AI compute applications, today announced the appointment of Syed Muhammad Nouman, FCA, as Group Finance Director, effective from July 20, 2026. Mr. Nouman will serve as the Company’s Principal Financial Officer and Principal Accounting Officer for SEC reporting purposes, as ratified by the Company’s Audit Committee. Mr. Nouman began his career at PwC, where he developed a strong foundation in audit and financial reporting. He is a Fellow Chartered Accountant (FCA) with mor

    7/20/26 9:00:00 AM ET
    $VIVO
    Power Generation
    Utilities

    VivoPower Reinforces Focus on AI Data Center Business and Provides Update on Non-Core Businesses

    LONDON, UNITED KINGDOM, July 02, 2026 (GLOBE NEWSWIRE) -- VivoPower PLC (NASDAQ:VIVO) ("VivoPower" or the "Company"), a B Corp-certified global developer and owner of powered land and data center infrastructure for AI compute applications, today provides the following update in respect of its strategic direction and the previously announced separation initiatives relating to its subsidiaries Tembo e-LV B.V. ("Tembo") and Caret Digital ("Caret Digital"). Following a strategic review, the Board of Directors of the Company has determined that VivoPower will focus, as a group and as its principal strategic priority, on the development and scale-up growth of its AI data center business and that

    7/2/26 5:25:00 PM ET
    $VIVO
    Power Generation
    Utilities

    VivoPower's B Corporation Recertification Strengthens Its Sovereign Infrastructure Mandate; Tembo Qualified to Use B Corp Logo

    VivoPower's recertification extends its continuous B Corp status to 2028, eight years after its initial certification in April 2018 The recertification provides verified third-party assurance of VivoPower's governance, environmental, and stakeholder accountability standards as the Company scales its sovereign AI data center platform across the Nordics, Western Europe, and the Middle East Tembo Group has qualified under B Lab's brand review process to use the B Corp logo on its website, in addition to VivoPower's own continued use of the logo LONDON, June 16, 2026 (GLOBE NEWSWIRE) -- VivoPower PLC (NASDAQ:VIVO) ("VivoPower" or the "Company"), a B Corp-certified global developer and owner

    6/16/26 8:15:00 AM ET
    $VIVO
    Power Generation
    Utilities

    $VIVO
    Financials

    Live finance-specific insights

    View All

    Meridian Bioscience, Inc. Enters into Agreement to Be Acquired by SD Biosensor and SJL Partners in $1.53 Billion All-Cash Transaction

    Shareholders to Receive $34.00 Per Share in Cash, Providing Immediate, Compelling and Certain Value Transaction Follows Deliberate Review, Including Outreach to Potential Strategic and Financial Partners CINCINNATI and SEOUL, South Korea, July 7, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. ("Meridian" or the "Company") (NASDAQ:VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, and SD Biosensor, Inc. ("SDB") (KOSE: A137310) and SJL Partners LLC ("SJL") (collectively, the "Consortium") announced today that they have entered into a definitive merger agreement whereby a newly formed affiliate vehicle of the Consortium will acquire Meridian in an a

    7/7/22 7:17:00 AM ET
    $VIVO
    Power Generation
    Utilities

    MERIDIAN BIOSCIENCE REPORTS RECORD SECOND QUARTER FISCAL 2022 OPERATING RESULTS

    CINCINNATI, May 6, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced financial results for the second quarter ended March 31, 2022. Second Quarter Fiscal 2022 Highlights (Comparison to Second Quarter Fiscal 2021): Consolidated net revenues totaled $111.2 million, the highest in Company history, with both segments ahead of expectationsLife Science segment delivered record net revenues of $70.1 millionDiagnostics segment net revenues increased 29% year-over-year to a record $41.1 millionLaunched Lyo-Ready™ sample specific master mixes for bloodResumed

    5/6/22 8:00:00 AM ET
    $VIVO
    Power Generation
    Utilities

    Meridian Acquires EUPROTEIN to Further Expand Recombinant Protein Capabilities

    CINCINNATI, Ohio, May 2, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ:VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that it has acquired, through its subsidiary Meridian Life Science, Inc., substantially all of the assets of EUPROTEIN Inc.  The transaction closed on April 30, 2022. EUPROTEIN Inc. offers custom development and production of high-quality bioresearch reagents, with a particular focus on human and other mammalian proteins and recombinant monoclonal antibodies.  This acquisition will help

    5/2/22 8:47:00 AM ET
    $VIVO
    Power Generation
    Utilities